← Eichor
Study identifier: NCT06202248 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

Condition: Non-metastatic Prostate Cancer · Locally Recurrent Prostate Cancer  ·  Sponsor: Alpha Tau Medical LTD.

PhaseNA
Planned participants10
Who can joinMale, 18 Years to 120 Years
Healthy volunteersNo

About this study

This is a multi-center clinical study enrolling up to 10 participants. The purpose of this study is to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of locally recurrent prostate cancer. Secondary objectives are to 1. To evaluate feasibility of interstitial radiotherapy using DaRT seeds. Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging \[Timeframe: immediately following the insertion procedure 2. To assess the impact of DaRT seeds on patient reported quality of life.

This description comes directly from the study's public registry record.

Talk to the study team

Liron Dimnik  ·  +972542688602  ·  LironD@alphatau.com

Aviya Hoida  ·  +972547869466  ·  aviyah@alphatau.com

Always discuss trial participation with your own doctor first.

Locations (1)

RAMBAM Health Care CampusHaifa, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06202248